Background Screening programs play an important role in a comprehensive strategy to prevent cervical cancer, a leading cause of death among women of reproductive age. Unfortunately, there is a dearth of information about rates of cervical cancer testing, particularly in Eastern Europe and Central Asia where levels of cervical cancer are among the highest in the WHO European Region. The purpose of this article is to report on the lifetime prevalence of cervical cancer testing among females aged 30–49 years from across the WHO European region, and to describe high-level geographic and socioeconomic differences. Methods We used data from the European Health Information Survey and the WHO STEPwise approach to Surveillance survey to calculate the proportions of women who were tested for cervical cancer. Results The percentage of tested women ranged from 11.7% in Azerbaijan to 98.4% in Finland, with the lowest percentages observed in Azerbaijan, Tajikistan and Uzbekistan. Testing was lower in Eastern Europe (compared to Western Europe), among low-income countries and among women with lower levels of education. Conclusion Effective cervical cancer screening programs are one part of a larger strategy, which must also include national scale-up of human papilloma virus vaccination, screening and treatment.

中文翻译：

---

世卫组织欧洲区域 30-49 岁女性的宫颈癌检测

背景 筛查计划在预防宫颈癌的综合战略中发挥着重要作用，宫颈癌是育龄妇女死亡的主要原因。不幸的是，缺乏关于宫颈癌检测率的信息，特别是在东欧和中亚，那里的宫颈癌水平在世卫组织欧洲区域中是最高的。本文的目的是报告世卫组织欧洲区域 30-49 岁女性中宫颈癌检测的终生患病率，并描述高水平的地理和社会经济差异。方法 我们使用来自欧洲健康信息调查和世卫组织逐步监测方法调查的数据来计算接受宫颈癌检测的女性比例。结果 接受测试的女性比例从阿塞拜疆的 11.7% 到芬兰的 98.4% 不等，阿塞拜疆、塔吉克斯坦和乌兹别克斯坦的比例最低。东欧（与西欧相比）、低收入国家和教育水平较低的女性的检测率较低。结论 有效的宫颈癌筛查计划是一项更大战略的一部分，该战略还必须包括在全国范围内扩大人乳头瘤病毒疫苗接种、筛查和治疗的规模。